News

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

In the phase 3 VALOR trial, oral brepocitinib 30 mg significantly improved myositis and skin disease activity versus placebo in treatment-refractory dermatomyositis.

A prospective cohort study found 94% of patients tolerated direct initiation at maintenance OIT dosing after brief omalizumab pretreatment.

Oral socrodeucitinib 12 mg significantly improved PASI 75 and sPGA responses versus placebo at Week 12 in a 125-patient phase 2 trial.

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

A new BEACON-HCC framework for liver cancer treatment matched expert decisions 96.6% of the time in a pilot study, outperforming BCLC 2025.

Stacey Rifkin-Zenenberg, DO, on early gene therapy outcomes and the long-term questions still being tracked in sickle cell disease.

Examining individual pregnancy outcomes rather than defining women by the presence or absence of complications more reliably predicts later CVD death.

A Stanford dermatologist explains how AI systems can reinforce racial bias in health care and underperform on skin cancer detection in darker skin.

In RESOLVE-Lung, the anti-GM-CSF antibody namilumab did not reduce rescue events or improve lung function versus placebo in chronic pulmonary sarcoidosis.

Robert Wood, MD, of Johns Hopkins University explains what the July 31 exit means for peanut oral immunotherapy and omalizumab-assisted desensitization.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Meagen McCusker, MD, discusses trusting instinct over rigid planning and why female physicians should lean on each other during career transitions.

Allergist Juanita Mora, MD, breaks down the ALA's COVID-19 prevention campaign — who needs a booster now, and how specialists can close the gap.

A prospective controlled study of 234 children finds food allergy raises ARFID-related picky eating and fear scores, but not appetite loss, Merve Karaca Şahin says.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Merck's sBLA seeks to extend clesrovimab-cfor (Enflonsia) coverage to children under 2 years at increased risk for severe RSV during their second season.

Stacey Rifkin-Zenenberg, DO, on gene therapy vs stem cell transplant and when to refer for sickle cell disease.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

The mRNA-based vaccine wins full approval for adults aged 50 to 64 years and accelerated approval for adults aged ≥ 65 years following unanimous VRBPAC backing.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.